ASH21
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
A recent study of brexu-cel supports its use for the treatment of MCL.
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Advertisement
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Frontline treatment of ibrutinib plus venetoclax induced deep responses in patients with previously untreated CLL.
Circulating tumor DNA accurately reflects tumor burden and may serve as a useful clinical biomarker for risk and outcome in ...
Advertisement
According to results presented at ASH 2021, the triplet combination of magrolimab plus azacitidine and venetoclax was safe.
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Dr. Daver shares results from a phase I/II study evaluating the addition of the anti-CD47 antibody magrolimab.
Induction and consolidation therapy with the combination induced responses in 98% of patients with newly diagnosed AML.
Three-quarters of evaluable patients experienced complete cytogenetic complete response.
Researchers shared a new single-cell multi-omic analysis of the genetic, cellular, and molecular landscape of TP53-driven.
Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217.
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.